Delivery Order SPE2DR25D7059-SPE2DR26F7MBE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30 count) valued at $4,336.18. This delivery order represents a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of November 4, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $14,672.56 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count). The contract is structured as a firm fixed price delivery order with a completion date of July 25, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this competitively awarded contract. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Telmisartan-HCTZ 40-12.5 mg tablet, unit dose, 30-count packages, with a ceiling value of $1,006.45. This is a firm fixed price, non-competitive delivery order with an ultimate completion date of September 25, 2025. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a $3,162.68 delivery order to AmerisourceBergen Drug Corp for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30 count) on November 10, 2025, with completion targeted for November 12, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The order represents a child contract under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Telmisartan-HCTZ 80-25 mg tablets in unit dose packaging (30-count). This competitively awarded, non-set-aside contract carries a ceiling value of $4,574.72 and is structured as a firm fixed-price delivery order with an ultimate completion date of August 13, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Telmisartan-HCTZ 80-25 mg tablet unit dose packages (30-count) with a ceiling value of $1,606.22. This is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $7,922.61 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count). This firm fixed-price contract, classified as a non-set-aside award, represents a competitive procurement through the federal medical supply chain system. The ultimate completion date is set for September 16, 2025, with performance occurring at the vendor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 20, 2025, for the supply of Telmisartan-HCTZ 80-12.5 mg tablets in unit dose packaging (30-count). This is a firm fixed price delivery order with a ceiling value of $2,059.94 and an ultimate completion date of June 23, 2025. The contract is unclassified and was competitively awarded without a set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $3,141.02 to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 11, 2025, with performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract involves no set-aside designation, reflecting open competition...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count). This is a firm fixed-price delivery order with a ceiling value of $5,374.94 and an ultimate completion date of June 17, 2025. The award is non-competitive with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child...
- SPE2DR25D7059Indefinite Delivery Contract
- SPE2DR25D7059-SPE2DR26F7MBEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count bottles) with a ceiling value of $1,064.79. This is a firm fixed-price delivery order with an ultimate completion date of November 18, 2025, and the work will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running through December 2026 that provides comprehensive pharmaceutical support to military healthcare systems worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for the Defense Health Agency and other government healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to deliver a broad range of pharmaceutical products and medical supplies, including brand-name and generic medications, vaccines, and specialized healthcare commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 11/17/25 |